Keymed Biosciences Narrows Loss in H1; CFO Steps Down

MT Newswires Live

Aug 26

Keymed Biosciences (HKG:2162) narrowed its attributable loss to 78.8 million yuan in the first half of 2025 from 336.7 million yuan a year prior, a Tuesday Hong Kong bourse filing said.

Loss per share for the biopharmaceutical firm was 0.30 yuan, down from 1.29 yuan in the year-ago period.

Revenue for the interim period increased 812% to 498.8 million yuan from 54.7 million yuan in the corresponding period of the last year.

In separate news, Yanrong Zhang resigned as the firm's chief financial officer effective immediately to devote more time to other commitments. Zhang will now act as a consultant for the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2562341527"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562341527\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562341527?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562341527","market":"hk","top_or_hot":-1,"title":"Keymed Biosciences Narrows Loss in H1; CFO Steps Down","media":"MT Newswires Live","content":"<html><body><p> Keymed Biosciences (HKG:2162) narrowed its attributable loss to 78.8 million yuan in the first half of 2025 from 336.7 million yuan a year prior, a Tuesday Hong Kong bourse filing said.</p><p>Loss per share for the biopharmaceutical firm was 0.30 yuan, down from 1.29 yuan in the year-ago period.</p><p>Revenue for the interim period increased 812% to 498.8 million yuan from 54.7 million yuan in the corresponding period of the last year.</p><p>In separate news, Yanrong Zhang resigned as the firm's chief financial officer effective immediately to devote more time to other commitments. Zhang will now act as a consultant for the company.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Biosciences Narrows Loss in H1; CFO Steps Down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Biosciences Narrows Loss in H1; CFO Steps Down\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-26 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Keymed Biosciences (HKG:2162) narrowed its attributable loss to 78.8 million yuan in the first half of 2025 from 336.7 million yuan a year prior, a Tuesday Hong Kong bourse filing said.</p><p>Loss per share for the biopharmaceutical firm was 0.30 yuan, down from 1.29 yuan in the year-ago period.</p><p>Revenue for the interim period increased 812% to 498.8 million yuan from 54.7 million yuan in the corresponding period of the last year.</p><p>In separate news, Yanrong Zhang resigned as the firm's chief financial officer effective immediately to devote more time to other commitments. Zhang will now act as a consultant for the company.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2562341527","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562341527","pubTimestamp":1756215501,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Keymed Biosciences  narrowed its attributable loss to 78.8 million yuan in the first half of 2025 from 336.7 million yuan a year prior, a Tuesday Hong Kong bourse filing said.Loss per share for the biopharmaceutical firm was 0.30 yuan, down from 1.29 yuan in the year-ago period.Revenue for the interim period increased 812% to 498.8 million yuan from 54.7 million yuan in the corresponding period of the last year.In separate news, Yanrong Zhang resigned as the firm's chief financial officer effective immediately to devote more time to other commitments. Zhang will now act as a consultant for the company.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"Keymed Biosciences上半年亏损收窄；首席财务官辞职","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":0.9},"content_text":"Keymed Biosciences (HKG:2162) narrowed its attributable loss to 78.8 million yuan in the first half of 2025 from 336.7 million yuan a year prior, a Tuesday Hong Kong bourse filing said.Loss per share for the biopharmaceutical firm was 0.30 yuan, down from 1.29 yuan in the year-ago period.Revenue for the interim period increased 812% to 498.8 million yuan from 54.7 million yuan in the corresponding period of the last year.In separate news, Yanrong Zhang resigned as the firm's chief financial officer effective immediately to devote more time to other commitments. Zhang will now act as a consultant for the company.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive,express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}